SMITH J. JEFFERSON 4

What Happened
Smith J. Jefferson, Chief Research Officer of Precision BioSciences (DTIL), had Restricted Stock Units (RSUs) vest and be settled into common shares on Jan 20–21, 2026 (conversion/exercise of derivatives). The filing shows acquisitions totaling 29,166 shares from RSU settlement (2,500 + 10,447 + 16,219). On Jan 21, he sold 10,200 shares in the open market at $4.03 per share, generating $41,106. The zero-dollar “disposed” derivative entries reflect the conversion/settlement of RSUs into shares.

Key Details

• Transaction dates: RSU vest/settlement on Jan 20–21, 2026; market sale on Jan 21, 2026.
• Sale details: 10,200 shares sold at $4.03 each for $41,106.
• Acquisitions: 29,166 shares acquired via RSU settlement (per Form 4 derivative entries).
• Footnotes: Sale was a sell-to-cover under a Rule 10b5-1 plan (adopted Apr 25, 2024); shares sold only to cover tax withholding. Each RSU equals one share. Filing notes 3,413 shares from the 2019 ESPP at $5.74 are included in reported holdings.
• Ownership after transaction: total shares owned after these transactions are not specified on this Form 4.
• Timeliness: Filing dated Jan 22, 2026 for transactions through Jan 21, 2026 — not indicated as late.

Context

• The Form 4 entries coded “M” reflect conversion/exercise of derivative awards (RSUs) into common shares. The subsequent open-market sale was a cashless, sell-to-cover transaction executed under a preplanned 10b5-1 arrangement to satisfy tax withholding — the filer notes no other shares were sold for other reasons.
• For retail investors: this is routine insider activity tied to RSU vesting and tax obligations, not an open-market bet for liquidity or sentiment; purchases generally signal more direct insider bullishness than sell-to-cover transactions.